Archive

Cannabis Rescheduling: The DEA's Proposed Rule and the Supporting OLC Opinion

By Jason Adelstone
May 21, 2024

The DEA published its proposed rule to move marijuana from schedule I to schedule III on May 21, and the 60-day public comment period has officially opened. The DEA also published an opinion from the Office of Legal counsel that provides a thorough analysis supporting why placing marijuana in schedule III is appropriate and legally justified. Read this insight for a high-level overview of the proposed rule and the OLC Opinion.

Read More

Marijuana Rescheduling Part II: Why Opponents Continue to Have No Idea What They Are Talking About

By Jason Adelstone
May 20, 2024

In a recent House Committee meeting with DEA Administrator Anne Milgram, Rep. Andrew S. Clyde voiced his opposition to removing marijuana from Schedule I based on public safety reasons, but then contradicted himself by stating marijuana is “not as dangerous as some of the others we have talked about” (the meeting focused primarily on fentanyl’s harms to communities). This blog post addresses the false narratives and misconceptions that opponents of cannabis reform continue to promote.

Read More

Vicente LLP Heads to Minneapolis for CANNRA 2024 External Stakeholder Meeting

May 16, 2024

Will you be in Minneapolis for the CANNRA 2024 External Stakeholder Meeting? Several members of the Vicente LLP team will be in attendance! Senior associate Jason Adelstone will discuss international considerations during the closing plenary on June 5, and partners Adam Fine and Michelle Bodian, director of regulatory policy Jen Flanagan, and counsel Jason Tarasek will also be in attendance!

Read More

Marijuana Rescheduling: Why Opponents Have No Idea What They Are Talking About

By Jason Adelstone
Apr 29, 2024

After listening to the House Oversight and Accountability Committee Hearing with the Commissioner of the FDA on April 11, one conclusion was reinforced—opponents of marijuana reform are misinformed and rely on misstating facts to support their position. Those against moving marijuana into schedule III are making their voices heard, but almost universally, those voices simply do not understand what schedule III would mean.

Read More

International Narcotics Control Board’s Use of “May” in 2023 Report Hints at Evolving Global Cannabis Stance

By Jason Adelstone
Mar 21, 2024

The International Narcotics Control Board (INCB) may be taking a more measured approach to cannabis. In their 2023 report, INCB used the word "may" when discussing potential inconsistencies between US state legalization and international treaties. This subtle shift in language suggests a more open-minded approach. This blog post explores the significance of this change in the report’s language and what it might mean for the future of global cannabis legalization.

Read More

Model Host Community Agreement Released by Massachusetts Cannabis Control Commission: What You Need to Know

By David M. Ullian, Tim Callahan
Mar 7, 2024

This Insights post provides an overview of recent changes impacting Massachusetts cannabis businesses. We break down the new Model Host Community Agreement (HCA), explaining its purpose, usage, and accessibility. Additionally, we explore the updated application and renewal processes, highlighting the mandatory inclusion of compliant HCAs or waivers. This blog serves as a valuable resource for both new and existing cannabis businesses seeking to navigate the evolving regulatory landscape in Massachusetts.

Read More

International Cannabis Update: Germany Joins Malta and Luxembourg in Liberalizing Marijuana Policy

By Jason Adelstone
Feb 27, 2024

Germany's recent enactment of a marijuana decriminalization bill marks a significant development in European drug policy. While falling short of full legalization, the new law allows for decriminalized possession, home cultivation, and participation in cannabis clubs. This blog post provides a concise overview of the new legislation, its potential impact, and its wider implications for the evolving European cannabis landscape.

Read More

The Massachusetts Cannabis Social Equity Trust Fund: What You Need to Know

By David M. Ullian
Feb 13, 2024

Massachusetts launched the Cannabis Social Equity Trust Fund to aid qualified cannabis businesses disproportionately impacted by marijuana prohibition. Licensed businesses or applicants meeting specific criteria, like Social Equity Program participants, can access grants or loans (up to $50,000 now!). Apply online and learn more about future programs before the February 15th deadline.

Read More

New Funding Opportunity for Maryland’s Social Equity Cannabis Business Applicants

By Meg Nash, Bridgette Nikisher
Feb 7, 2024

Maryland's Cannabis Business Assistance Loan/Grant Fund is offering grants to help social equity applicants cover costs associated with obtaining a cannabis business license. The program reimburses up to 50% of eligible expenses, with a maximum of $5,000. Applications open February 19th and close March 20th. Read this Insights post to learn more about eligibility, qualifying expenses, and how to apply.

Read More

The DEA’s Scheduling of Marijuana: What Happens After the DEA Publishes Its Rule?

By Jason Adelstone
Jan 30, 2024

On August 29, 2023, the Department of Health and Human Services (“HHS”) sent the Drug Enforcement Administration (“DEA”) its recommendation to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). Since then, the marijuana industry has waited in suspense for the DEA to make the final call as to what schedule marijuana will be placed. Read this Insights post that outlines the complex process of marijuana rescheduling in the US and outlines the key steps involved, from rule publication to review and final rule, emphasizing the critical role of stakeholder engagement in securing a Schedule III classification.

Read More

A Potential Breakthrough for Psychedelic Treatments: Ninth Circuit Court Ruling on Psilocybin Rescheduling

By Jason Adelstone
Dec 7, 2023

On October 27, 2023, the Ninth Circuit Court of Appeals, in Aggarwal v. DEA, held that the U.S. Drug Enforcement Agency (DEA) must reconsider its denial of a petition to transfer psilocybin, the active ingredient in “magic mushrooms” from Schedule I to Schedule II. Read this Insights post for more information about the Ninth Circuit Court’s order to reschedule psilocybin.

Read More

Top Five Countries to Watch for International Cannabis Reform in 2024

By Jason Adelstone
Nov 6, 2023

While the cannabis industry in the United States awaits a marijuana scheduling decision from the DEA, many countries around the world continue to move forward with liberalizing their cannabis policies as a superior method of promoting the health and welfare of their citizens. In this blog post, we’ll take a closer look at five countries poised to make waves in the cannabis landscape in 2024, including Germany, Thailand, Colombia, the Czech Republic, and Switzerland.

Read More

New Cannabis Regulations in Massachusetts Are Now in Effect: What You Need to Know

By David Ullian
Oct 31, 2023

The Massachusetts Cannabis Control Commission’s amended regulations make substantial changes to the current regulatory framework related to HCAs, Social Equity businesses, municipal equity, and agent suitability. These changes reveal a clear intent to make real progress towards achieving the goals of creating new opportunities and a level playing field for Social Equity businesses, and continuing to build a successful, equitable cannabis industry in Massachusetts. Read this article for an overview of the key provisions in the amended regulations.

Read More

The Duality of Cannabis Regulation According to the International Narcotics Control Board: A Response to the Report of the INCB for 2022

By Jason Adelstone
Mar 15, 2023

In its 2022 report, the International Narcotics Control Board (INCB) argues that legalizing the non-medical and non-scientific use of cannabis has failed to achieve the benefits to society that were intended through such legalization. In its attempt to deliver evidence of this failure, INCB instead provides ample evidence to the contrary—that legalization and regulation work. Read this insight for Vicente LLP’s response to the annual report of the INCB.

Read More

The Evolution of the Cannabis Industry in Massachusetts

By David Ullian, Jennifer Flanagan
Nov 2, 2022

This Bloomberg Law article by David Ullian and Jen Flanagan explores the evolution of the Massachusetts adult-use cannabis industry and how lawmakers, regulators, and industry advocates contributed to key recent legislative and regulatory developments.

Read More

[Webinar] Massachusetts Cannabis Regulatory Update

Aug 19, 2022

Massachusetts Legislature recently voted to pass marijuana reform legislation that will impact the cannabis industry in significant ways, particularly with respect to social equity. Watch this for an overview of the new law and insights into how it might impact your business.

Read More

5 Years of Legal Cannabis in Massachusetts

By David M. Ullian, Gabriel Amatruda
Nov 8, 2021

Five years in, the Commonwealth has seen the most significant growth in both the number of cannabis businesses and sales, and the market continues to expand and provide new opportunities.

Read More

How to Get a Medical Marijuana Card via Telemedicine

By Charles Alovisetti, Brandon Kurtzman
Apr 16, 2020

Since COVID-19 has limited patient ability to get in-person consultations and examinations with health care providers, how does one go about obtaining a medical marijuana patient certification?

Read More

New Massachusetts Medical and Adult Use Marijuana Regulations

By David Ullian, Senior Associate Attorney; Meg Nash, Associate Attorney; Casey Leaver, Compliance Manager
Nov 1, 2019

With the release of the new marijuana regulations in Massachusetts, our attorneys created a list of some of the important amended licensing and operational topics, effective Friday, November 1, 2019.

Read More